Daily Stock Analysis, IDXG, Interpace Diagnostics Group Inc, priceseries

Interpace Diagnostics Group Inc. Daily Stock Analysis
Stock Information
Open
0.75
Close
0.69
High
0.76
Low
0.68
Previous Close
0.79
Daily Price Gain
-0.10
YTD High
1.12
YTD High Date
Jan 22, 2019
YTD Low
0.67
YTD Low Date
Jun 7, 2019
YTD Price Change
-0.22
YTD Gain
-24.30%
52 Week High
1.25
52 Week High Date
Nov 15, 2018
52 Week Low
0.67
52 Week Low Date
Jun 7, 2019
52 Week Price Change
-0.50
52 Week Gain
-42.11%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
7.50
Jan 4. 2017
8.54
1 Trading Days
13.80%
Link
LONG
Mar 21. 2017
2.45
Mar 23. 2017
2.59
2 Trading Days
5.63%
Link
LONG
Aug 15. 2017
1.08
Sep 13. 2017
1.47
20 Trading Days
35.93%
Link
LONG
Jul 12. 2018
0.92
Jul 31. 2018
1.04
13 Trading Days
12.82%
Link
LONG
Aug 20. 2018
1.05
Sep 11. 2018
1.43
15 Trading Days
35.73%
Link
Company Information
Stock Symbol
IDXG
Exchange
NasdaqCM
Company URL
http://www.interpacediagnostics.com
Company Phone
412-224-6100
CEO
Jack E. Stover
Headquarters
New Jersey
Business Address
MORRIS CORPORATE CENTER 1,, BUILDING C, 300 INTERPACE PARKWAY, PARSIPPANY, NJ 07054
Sector
-
Industry Category
-
Industry Group
-
CIK
0001054102
About

Interpace Diagnostics Group, Inc. provides commercialization services to biopharmaceutical companies. It focuses on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for patient diagnosis and management. The company offers commercialized molecular tests which include PancraGen, ThyGenX, and ThyraMIR. PancraGen for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.

Description

PDI, Inc. provides outsourced commercial services to pharmaceutical, biotechnology, diagnostics, and healthcare companies in the United States. It operates in two segments, Commercial Services and Interpace Diagnostics. The Commercial Services segment offers outsourced sales teams that target healthcare providers, providing a range of complementary sales support services designed to achieve its customers' strategic and financial product objectives. This segment offers a range of personal and non-personal promotional options for the commercialization of their products throughout the product lifecycles, from development through maturity. It also provides other promotional services, including clinical educator, teledetailing, and full product commercialization services. This segment’s services include product distribution, personal and non-personal product detailing, full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management. The Interpace Diagnostics segment focuses on developing and commercializing molecular diagnostic tests for physicians and patients with diagnostic options for detecting genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. This segment offers PancraGen, a diagnostic test designed for determining risk of malignancy in pancreatic cysts; and ThyGenX, a next-generation sequencing test designed to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules. It also has three diagnostic tests in late stage development that are designed to detect genetic alterations that are associated with gastrointestinal cancers; and one diagnostic test in late stage development that is designed to detect genetic alterations that are associated with endocrine cancers. PDI, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.